Global PEGylated Proteins Market Growth 2023-2029

Global PEGylated Proteins Market Growth 2023-2029

PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s.
LPI (LP Information)' newest research report, the “PEGylated Proteins Industry Forecast” looks at past sales and reviews total world PEGylated Proteins sales in 2022, providing a comprehensive analysis by region and market sector of projected PEGylated Proteins sales for 2023 through 2029. With PEGylated Proteins sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PEGylated Proteins industry.
This Insight Report provides a comprehensive analysis of the global PEGylated Proteins landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PEGylated Proteins portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global PEGylated Proteins market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PEGylated Proteins and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PEGylated Proteins.
The global PEGylated Proteins market size is projected to grow from US$ 3687 million in 2022 to US$ 4833 million in 2029; it is expected to grow at a CAGR of 4833 from 2023 to 2029.
The major players in global PEGylated Proteins market include UCB, Pfizer, etc. The top 2 players occupy about 60% shares of the global market. North America and Europe are main markets, they occupy over 60% of the global market. Colony Stimulating Factors and Interferons are two main types, with a share over 40% altogether. Rheumatoid Arthritis & Crohn's Disease and Cancer Treatment are two key applications, they hold about 60% shares.
This report presents a comprehensive overview, market shares, and growth opportunities of PEGylated Proteins market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Colony Stimulating Factors
Interferons
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibodies
Others
Segmentation by application
Cancer Treatment
Hepatitis
Chronic Kidney Disease
Leukemia
SCID
Rheumatoid Arthritis & Crohn's Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ENZON Pharmaceuticals
Merck Sharp & Dohme
Roche
Pfizer
Amgen
UCB
Crealta (Savient)
Key Questions Addressed in this Report
What is the 10-year outlook for the global PEGylated Proteins market?
What factors are driving PEGylated Proteins market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PEGylated Proteins market opportunities vary by end market size?
How does PEGylated Proteins break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.